Details for Patent: 11,541,012
Which drugs does patent 11,541,012 protect, and when does it expire?
Patent 11,541,012 protects KHAPZORY and is included in one NDA.
Summary for Patent: 11,541,012
| Title: | Compositions comprising disodium levofolinate |
| Abstract: | Provided herein are compositions comprising disodium levofolinate. Also provided are processes for preparing compositions comprising disodium levofolinate. Also provided are compositions comprising disodium levofolinate prepared by the processes provided herein. Also provided are methods of treating folic acid deficiency in a subject in need thereof, comprising administering a composition provided herein to the subject. Also provided are methods of treating cancer in a subject in need thereof, comprising administering 5-fluorouracil and a composition provided herein to the subject. Also provided are methods of reducing the immediate toxic effects of methotrexate overdose in a subject in need thereof, comprising administering a composition provided herein to the subject. Also provided are methods of treating cancer in a subject in need thereof, comprising administering high-dose methotrexate and a composition provided herein to the subject. Also provided are methods of treating megaloblastic anemia in a subject in need thereof, comprising administering a composition provided herein to the subject. |
| Inventor(s): | Ramsharan Singh, Bahman Shimiaei |
| Assignee: | Acrotech Biopharma LLC |
| Application Number: | US16/257,684 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,541,012 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Process; |
Drugs Protected by US Patent 11,541,012
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acrotech Biopharma | KHAPZORY | levoleucovorin | POWDER;INTRAVENOUS | 211226-001 | Oct 19, 2018 | RX | Yes | Yes | 11,541,012 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Acrotech Biopharma | KHAPZORY | levoleucovorin | POWDER;INTRAVENOUS | 211226-002 | Oct 19, 2018 | DISCN | Yes | No | 11,541,012 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
